Cogent Biosciences Inc (NASDAQ: COGT) has unveiled details related to its ongoing Phase 2 APEX clinical trial. It was a trial that targeted the evaluation of bezuclastinib. The substance in question is a selective KIT D816V inhibitor, and the company wanted to discover its impact on patients struggling with advanced systemic mastocytosis (AdvSM).
The 2022 European Hematology Association (EHA) Congress in Vienna provided a platform for scientists to present data from the study. They intend to make the presentation in the form of a poster presentation.
The Chief of the Division of Leukemia at the Dana-Farber Cancer Institute, Daniel DeAngelo, elaborates on the matter. He says the Advanced systemic mastocytosis is a debilitating and severe hematologic condition. It continues giving patients and physicians sleepless nights searching for better working solutions. In other words, they are trying to look for the better tolerated and more effective treatment options to counter the disorder.
Daniel is pleased with the early results they obtained and announced today and seems optimistic about the future. He projects that similar results in a larger set of patients with AdvSM could reveal a lot about the product’s effectiveness. He firmly asserts that bezuclastinib is the product that could give them the power and capacity to help patients struggling with systemic mastocytosis.
Andrew speaks out
The Chief Executive Officer at Cogent Biosciences, Andrew Robbins, is the other leader who has been quick to comment on the unveiling of the data. He expresses great excitement and describes the data from the APEX study of bezuclastinib in advanced systemic mastocytosis as rather inspiring. Andrew is confident that the study’s outcome reinforces an encouraging hypothesis that inspires hope among current and future patients.
He says the hypothesis points out that a selective KIT D816V inhibitor could deliver an outstanding clinical activity to all systemic mastocytosis patients, provided it functions with limited CNS penetration. The point of concern is to treat patients with a product that won’t present tolerability challenges. Most of the treatments in the markets pose serious challenges.
Andrew is impressed with the results and looks towards a future where they will freely accelerate their investments and timelines. They might unveil another APEX clinical update before the year ends.